Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alpha Difluoromethyl Ornithine
2. Alpha Difluoromethylornithine
3. Alpha-difluoromethyl Ornithine
4. Alpha-difluoromethylornithine
5. Difluoromethylornithine
6. Dl Alpha Difluoromethylornithine
7. Dl-alpha-difluoromethylornithine
8. Eflornithine
9. Eflornithine Monohydrochloride, Monohydrate
10. Mdl 71,782 A
11. Mdl-71,782 A
12. Mdl71,782 A
13. Ornidyl
14. Ornithine, Alpha-difluoromethyl
15. Rmi 71782
16. Vaniqa
1. 68278-23-9
2. Eflornithine Hcl
3. Dfmo
4. Dl-alpha-difluoromethylornithine Hydrochloride
5. Eflornithinehydrochloride
6. 2-(difluoromethyl)-dl-ornithine Monohydrochloride
7. Eflornithine Hydrochloride Anhydrous
8. Dfmo Hcl
9. Eflornithine (hydrochloride)
10. Dfmo Hydrochloride
11. 2,5-diamino-2-(difluoromethyl)pentanoic Acid Hydrochloride
12. Vaniqa
13. Dfmo Hcl;eflornithine Hcl
14. Uo07o10tcj
15. Mls000069341
16. 2,5-diamino-2-(difluoromethyl)pentanoic Acid;hydrochloride
17. D,l-alpha-difluoromethylornithine Hydrochloride
18. Nsc-270295
19. H-alpha-difluoro-me-dl-orn-oh Hcl Ho
20. Ncgc00093850-01
21. Smr000058442
22. .alpha.-dfmo Hcl
23. Dsstox_cid_25765
24. Dsstox_rid_81107
25. Eflornithine . Hcl . Ho;dfmo . Hcl . Ho;alpha-difluoromethylornithine . Hcl . Ho
26. Dsstox_gsid_45765
27. Dfmo;mdl71782;rmi71782;alpha-difluoromethylornithine
28. Dl-ornithine, Monohydrochloride
29. Cas-96020-91-6
30. Ccris 5805
31. Nsc-337250
32. Einecs 269-532-0
33. Unii-uo07o10tcj
34. Sr-01000076229
35. 2-(difluoromethyl)-dl-ornithine Hydrochloride
36. 2-(difluoromethyl)-dl-ornithine Hcl
37. Dl-ornithine, 2-(difluoromethyl)-, Monohydrochloride
38. Nsc 270295
39. Nsc 337250
40. Opera_id_46
41. Eflornithine Hydrocloride
42. Ornithine, 2-(difluoromethyl)-, Monohydrochloride
43. Mls001332583
44. Chembl536971
45. Schembl3022583
46. (rs)-eflornithine Hydrochloride
47. Hy-b0744a
48. Dtxsid601019072
49. L-eflornithine Hydrochloride
50. Bcp11748
51. Dl-alpha-difluoromethylornithine Hcl
52. Tox21_111224
53. Tox21_500429
54. Ac-388
55. Mfcd00274036
56. Nsc270295
57. Akos015895186
58. Tox21_111224_1
59. Ccg-221733
60. Eflornithine Hydrochloride [mi]
61. Ks-1261
62. Lp00429
63. 2-(difluoromethyl)ornithine Hydrochloride
64. Ncgc00015316-05
65. Ncgc00261114-01
66. Dl-
67. A-difluoromethylornithine Hydrochloride
68. E0947
69. Eu-0100429
70. Ft-0630774
71. Dl-2-(difluoromethyl)-ornithine Hydrochloride
72. H-alpha-difluoro-me-dl-orn-oh . Hcl . Ho
73. Dl- Alpha -difluoromethylornithine Hydrochloride
74. 278e239
75. A836071
76. A836749
77. Dl--difluoromethylornithine Hydrochloride Monohydrate
78. Sr-01000076229-1
79. Dl-alpha-difluoromethylornithine Hydrochloride Hydrate
80. Q27291165
81. 2,5-diamino-2-(difluoromethyl)pentanoic Acid,hydrochloride
82. 2,5-bis(azanyl)-2-[bis(fluoranyl)methyl]pentanoic Acid Hydrochloride
83. 2,5-diamino-2-(difluoromethyl)pentanoic Acid Hydrochloride;eflornithine Hcl
84. 2,5-diamino-2-(difluoromethyl)pentanoic Acid, Monohydrochloride
Molecular Weight | 218.63 g/mol |
---|---|
Molecular Formula | C6H13ClF2N2O2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 218.0633617 g/mol |
Monoisotopic Mass | 218.0633617 g/mol |
Topological Polar Surface Area | 89.3 Ų |
Heavy Atom Count | 13 |
Formal Charge | 0 |
Complexity | 166 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Treatment of facial hirsutism in women.
Trypanocidal Agents
Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Ornithine Decarboxylase Inhibitors
Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)
D11AX
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31780
Submission : 2017-06-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11932
Submission : 1996-04-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18509
Submission : 2005-07-12
Status : Active
Type : II
About the Company : Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction & pain management. We manufacture & market a wide range of APIs & formul...
About the Company : EUROAPI is the market leader in small molecule APIs with projected sales of about €1 billion in 2022. With around 200 APIs, it has one of the largest portfolios in the market. Th...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...
About the Company : Micro Orgo Chem is a pharmaceutical establishment, manufacturing niche Active Pharmaceutical Ingredients (API). Founded in 1992, we have a mission of providing high quality drugs t...
About the Company : OmnisMed Pharmaceuticals believes that good healthcare must be accessible to everyone; That is the core of our philosophy. We are experts in providing a wide range of high-quality ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
CPP-1X-S (eflornithine) sachets is an ornithine decarboxylase inhibitor being evaluated in the IND stage for treating STK11 mutant non-small cell lung cancer (NSCLC).
Lead Product(s): Eflornithine Hydrochloride,Pembrolizumab
Therapeutic Area: Oncology Brand Name: CPP-1X-S
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2024
Lead Product(s) : Eflornithine Hydrochloride,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Patient Enrolled in STK11 Mutant Lung Cancer Trial at Moffitt
Details : CPP-1X-S (eflornithine) sachets is an ornithine decarboxylase inhibitor being evaluated in the IND stage for treating STK11 mutant non-small cell lung cancer (NSCLC).
Brand Name : CPP-1X-S
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 24, 2024
Details:
Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: Iwilfin
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Norgine Submits MAA for Eflornithine in High-Risk Neuroblastoma via Project Orbis
Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.
Brand Name : Iwilfin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Details:
CPP-1X-T (eflornithine) is a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes. It is approved by USFDA for the treatment of Pediatric Neuroblastoma.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: CPP-1X-T
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: US WorldMeds
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : US WorldMeds
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CPP-1X-T (eflornithine) is a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes. It is approved by USFDA for the treatment of Pediatri...
Brand Name : CPP-1X-T
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 18, 2023
Details:
Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: Iwilfin
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggre...
Details : Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Brand Name : Iwilfin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2023
Details:
Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: Iwilfin
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Eflornithine for Adult and Pediatric Patients with High-Risk Neuroblastoma
Details : Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Brand Name : Iwilfin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2023
Details:
DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, which is investigated in combination with eflornithine in patients newly diagnosed with glioblastoma.
Lead Product(s): Eflornithine Hydrochloride,Temozolomide
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Lead Product(s) : Eflornithine Hydrochloride,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, which is investigated in combination with eflornithine in patients newly diagnosed with glioblastoma.
Brand Name : DFMO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2023
Details:
Panbela has divested certain assets in its eflornithine pediatric neuroblastoma program including, CPP-1X (eflornithine), being developed for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: CPP-1X
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: US WorldMeds
Deal Size: $9.5 million Upfront Cash: Undisclosed
Deal Type: Divestment July 19, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : US WorldMeds
Deal Size : $9.5 million
Deal Type : Divestment
Details : Panbela has divested certain assets in its eflornithine pediatric neuroblastoma program including, CPP-1X (eflornithine), being developed for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 d...
Brand Name : CPP-1X
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 19, 2023
Details:
The agreement is for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial is evaluating the maximum tolerated dose of CPP-1X (eflornithine).
Lead Product(s): Eflornithine Hydrochloride,Pembrolizumab
Therapeutic Area: Oncology Brand Name: CPP-1X
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Moffitt Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 22, 2023
Lead Product(s) : Eflornithine Hydrochloride,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement is for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial is evaluating the maximum tolerated dose of CPP-1X (eflornithine).
Brand Name : CPP-1X
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 22, 2023
Details:
CPP-1X-T (eflornithine) is being developed as a single agent tablet or high dose power sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Endocrinology Brand Name: CPP-1X-T
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: JDRF
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : JDRF
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CPP-1X-T (eflornithine) is being developed as a single agent tablet or high dose power sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes.
Brand Name : CPP-1X-T
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 12, 2023
Details:
Panbela has regained the North American rights to develop and commercialize Flynpovi (the combination of CPP-1X (eflornithine hydrochloride) and sulindac) in patients with FAP. The drug is withdrawn form the european market and company will conduct FAP trial for phase 3.
Lead Product(s): Eflornithine Hydrochloride,Sulindac
Therapeutic Area: Oncology Brand Name: Flynpovi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: One-Two Therapeutics Assets Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 11, 2023
Lead Product(s) : Eflornithine Hydrochloride,Sulindac
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : One-Two Therapeutics Assets Limited
Deal Size : Undisclosed
Deal Type : Termination
Details : Panbela has regained the North American rights to develop and commercialize Flynpovi (the combination of CPP-1X (eflornithine hydrochloride) and sulindac) in patients with FAP. The drug is withdrawn form the european market and company will conduct FAP t...
Brand Name : Flynpovi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 11, 2023
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
19 Aug 2019
Reply
12 Jul 2019
Reply
03 Apr 2019
Reply
04 Dec 2018
Reply
13 Jul 2018
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?